Abstracts Archive - Page 487 of 2425 - ACR Meeting Abstracts

Abstract Number: PP12 • ACR Convergence 2022
We Became Advocates, Educators, and a Support System for Hispanic/Latino Patients with Rheumatoid Arthritis and Their Caregivers Through Involvement in a Virtual Patient Advisory Board
Zucy Almonacid¹, Wigna Cruz², Francisca Garcia³, Teresa Hernandez⁴, Velia Martinez⁵, Patricia Mattos³, Mario Mutis⁶ and Denise Serrano⁷, ¹Hicsville, NY, ²Juan Diaz, PR, ³Lake Worth, FL, ⁴Greenacres, FL, ⁵Guaynabo, PR, ⁶Fort Pierce, FL, ⁷Toa Alto, PR
Background/Purpose: Each of us has been diagnosed with rheumatoid arthritis (RA), from as recently as one year ago to as long as 20 years ago.…
Abstract Number: PP04 • ACR Convergence 2022
Invisible to Invincible: The Role of Virtual Events in Autoimmune Advocacy, Education and Community Building
Kara Wada, The Ohio State University, Columbus, OH
Background/Purpose: After years of ignoring my dry eyes and mouth, unrelenting fatigue, and body pain, an off-the-cuff comment from my dental hygienist finally pushed me…
Abstract Number: 2246 • ACR Convergence 2022
Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on themes in rheumatoid arthritis (RA) patients' treatment goals which associated with aspects of rheumatology care such as presence of a…
Abstract Number: PP23 • ACR Convergence 2022
The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient
Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY
Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in…
Abstract Number: PP25 • ACR Convergence 2022
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
Shung Chiu¹ and Mei Nee Chiu², ¹Spondylitis Association of America, Ludhiana, Punjab, India, ²University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India
Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
Abstract Number: PP10 • ACR Convergence 2022
How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology
Brooklyn Johnson¹ and Kathleen Collins², ¹Memphis, TN, ²LeBonheur Children's Hospital, Memphis, TN
Background/Purpose: The summer before my senior year, I developed a faint rash on my face and my arms. At a dermatology appointment, I pointed this…
Abstract Number: PP16 • ACR Convergence 2022
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
Ashley Krivohlavek, Oklahoma City, OK
Background/Purpose: At age 12, I was diagnosed with psoriasis (PsO) followed by a diagnosis of psoriatic arthritis (PsA) at age 30. I'm now 38. In…
Abstract Number: PP22 • ACR Convergence 2022
Patients Raising Awareness for Patients – A Collaborative Partnership Between Take a Pain Check Foundation and Canadian Arthritis Patient Alliance
Natasha Trehan¹ and Laurie Proulx², ¹Take a Pain Check Foundation, Markham, ON, Canada, ²Canadian Arthritis Patient Alliance, Ottawa, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis is a chronic disease that affects a child's school life and relationships, creating social isolation for youth and young adults. Take…
Abstract Number: PP18 • ACR Convergence 2022
From Devastated to Empowered: How Patient Engagement in Research Changes Lives
Eileen Davidson, Burnaby, BC, Canada
Background/Purpose: In April of 2015 I was a 29 year-old single mom diagnosed with rheumatoid arthritis (RA). RA wasn't unknown to me; my aunt who…
Abstract Number: 2241 • ACR Convergence 2022
Autoantibodies and Damage in Patients with Idiopathic Inflammatory Myopathies: A Longitudinal Multicenter Study from the EuroMyositis International Network
Fabricio Espinosa-Ortega¹, Karin Lodin², Marie Holmqvist¹, Maryam Dastmalchi³, Angela Ceribelli⁴, Jiri Venkovsky⁵, Hector Chinoy⁶, Louise Diederichsen⁷, Samuel Shinjo⁸, Ingrid Lundberg⁹ and Helene Alexanderson¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska University hospital, Huddinge, Sweden, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ⁵Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic, Prague, Czech Republic, ⁶The University of Manchester, Sale, United Kingdom, ⁷Copenhagen University Hospital, Rigshospitalet, Dragør, Denmark, ⁸Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ⁹Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) may harbor autoantibodies that are associated with well-defined clinical phenotypes. The association of these autoantibodies with level of…
Abstract Number: 2236 • ACR Convergence 2022
Association of microRNA-30b Plasma Expression with Fibromyalgia Clinical Features and with Corneal Small Nerve Fiber Pathology
Laura Aline Martínez Martínez¹, Fausto Sánchez Muñoz¹, Manuel Ramírez Fernández², Yaneli Juárez Vicuña¹, Mario Peña-Peña¹, Carlos Alfonso Guzman Martin¹, Itzel Palafox Sosa¹ and Manuel Martínez-Lavín¹, ¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ²APEC Hospital de la ceguera, Ciudad de México, Mexico
Background/Purpose: There is a clear association between fibromyalgia and small fiber neuropathy. Dorsal root ganglia contain the small nerve fiber nuclei. Severe fibromyalgia is associated…
Abstract Number: PP08 • ACR Convergence 2022
Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)
Ela Chintagunta¹, Courtney Wells² and Kristine Carandang³, ¹Young Patients' Autoimmune Research & Empowerment Alliance, Chicago, IL, ²University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN, ³Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA
Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of 13 when I was experiencing joint swelling in my lower body and my…
Abstract Number: 2239 • ACR Convergence 2022
Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial
Rohit Aggarwal¹, Christina Charles-Schoeman², joachim Schessl³, Victoria Werth⁴, Zsuzsanna Bata-Csorgo⁵, Mazen Dimachkie⁶, Zoltan Griger⁷, Sergey Moiseev⁸, Chester Oddis⁹, Elena Schiopu¹⁰, Jiří Vencovský¹¹, Irene Beckmann¹², Elisabeth Clodi¹³, Todd Levine¹⁴ and and the ProDERM investigators¹⁵, ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ³Friedrich-Baur-Institut/Medical University Munich, Mainkofen, Germany, ⁴Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁵University of Szeged, Faculty of Medicine, Szeged, Hungary, ⁶University of Kansas Medical Center, Kansas City, KS, ⁷University of Debrecen, Debrecen, Hungary, ⁸First Moscow State Medical University, Moscow, Russia, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ¹¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹²Octapharma PharmazeutikaProduktionsGesmbH, Vienna, Austria, ¹³Octapharma Pharmazeutika ProduktionsgesmbH, Vienna, Austria, ¹⁴Phoenix Neurological Associates, Ltd., Phoenix, AZ, ¹⁵Institutions in Europe and North America, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rashes and progressive proximal muscle weakness. The efficacy of IVIg treatment in…
Abstract Number: 1786 • ACR Convergence 2022
Anterior Knee Pain Is Associated with 2-year Compartment Specific Patellofemoral Cartilage Worsening: The MOST Study
Corey Lanois¹, Natalie Collins², Tuhina Neogi³, Ali Guermazi⁴, Frank Roemer⁵, Michael LaValley⁶, Michael Nevitt⁷, James Torner⁸, Cora E. Lewis⁹ and Joshua Stefanik¹⁰, ¹Northeastern University, Providence, RI, ²University of Queensland, Brisbane, Australia, ³Boston University School of Medicine, Boston, MA, ⁴Boston University, Boston, MA, ⁵Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany, ⁶Boston University School of Public Health, Arlington, MA, ⁷University of California at San Francisco, Orinda, CA, ⁸University of Iowa, Iowa City, IA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Northeastern University, Boston, MA
Background/Purpose: Anterior knee pain (AKP) may be a precursor to patellofemoral osteoarthritis (PFOA). Cross-sectionally, frequent AKP has been associated with MRI features of PFOA; however,…
Abstract Number: 1785 • ACR Convergence 2022
PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort
Susan Bartlett¹, orit schieir², Marie-France Valois², Janet Pope³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Carter Thorne⁸, Diane Tin⁹, Glen Hazlewood¹⁰ and Vivian Bykerk¹¹, ¹McGill University, Montreal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].